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 Abstract 
The importance of metabolism in macrophage function has been reported, but 
the in vivo relevance of the in vitro observations is still unclear. Here we show that 
macrophage metabolites are defined in a specific tissue context, and these metabolites 
are crucially linked to tissue-resident macrophage functions. We find the peritoneum to 
be rich in glutamate, a glutaminolysis-fuel that is exploited by peritoneal-resident 
macrophages to maintain respiratory burst during phagocytosis via enhancing 
mitochondrial complex II metabolism. This niche-supported, inducible mitochondrial 
function is dependent on protein kinase C activity, and is required to fine-tune the 
cytokine responses that control inflammation. Additionally, we find that peritoneal-
resident macrophage mitochondria are recruited to phagosomes and produce 
mitochondrially-derived reactive oxygen species which are necessary for microbial killing. 
We propose that tissue-resident macrophages are metabolically poised in situ to protect 
and exploit their tissue-niche by utilizing locally available fuels to implement specific 
metabolic programs upon microbial sensing.  
 Introduction 
Tissue-resident macrophages (TRMØ) are tissue-specialized immune sentinels, 
which have key functions in homeostasis and inflammation1, 2. Like many TRMØ, 
peritoneal TRMØ (pTRMØ) are not originally derived from monocytes, but rather from 
embryonic progenitors seeded into tissues before birth, with the populations maintained 
by local-proliferation3, 4, 5, 6. These cells exist in complex environments and do not fit 
traditional polarization categories, such as LPS and interferon-? stimulated pro-
inflammatory (M1) and interleukin-4 stimulated anti-inflammatory (M2)2, 7. It has been 
shown that tissue-niche environments can govern cell phenotype via epigenetic 
programming8, 9. The precise factors responsible for this in situ programming are largely 
uncategorized, although peritoneal retinoic acid can induce Gata6 expression10 to dictate 
pTRMØ phenotype10, 11, 12. However, the metabolic repertoire of in situ environments are 
largely unknown, and it is likely that other metabolites will govern resident cell functions 
in their respective tissues2. 
There has been resurgent interest in metabolic control of cellular function, 
particularly in immunology13, 14, 15. In bone-marrow derived macrophages (BMDM), M1 
macrophage differentiation in vitro and functional responses, including cytokine 
production, are dependent on glucose and glutamine metabolism, whereas the M2 
phenotype reportedly relies on fatty acid oxidation for oxidative phosphorylation 
(OXPHOS), and on glutamine for protein modifications15, 16. However, M2 differentiation 
itself does not require long-chain fatty acid oxidation17, 18. By contrast, little is known 
 about TRMØ metabolism, or which fuels are available in tissue-niches that govern cell 
function2.  
Macrophage biology encompasses common and tissue-niche functions. For 
example, pTRMØ invade peritoneal organs and facilitate repair19, supporting their 
physiological importance. However, TRMØ are also the front-line immune-sentinels that 
possess primary macrophage functions including phagocytosis and respiratory burst20. 
TRMØ express a repertoire of pattern-recognition receptors, including Dectin-121, 
mannose receptor and multiple toll-like receptors. These receptors engage microbes to 
promote phagocytosis and assembly of NADPH oxidase (NOX) 2 that supports oxidative 
respiratory burst22. While respiratory burst and the signalling mechanisms which support 
it are understood in neutrophils, the metabolic requirements of respiratory burst are not 
clear in TRMØ. 
Here our results link the availability of peritoneal fuels and requirements for 
pTRMØ metabolic processes that sustain respiratory burst. Resting pTRMØ are resistant 
to nutrient depletion and have very little basal mitochondrial complex II (CII) activity. 
However, upon phagocytosis or metabolic stress, pTRMØ utilize peritoneal metabolites 
to promote an enhancement in glutaminolysis-fuelled CII metabolism that facilitates 
respiratory burst required for microbial control and immune function. 
 Results 
PTRMØ have a substantial glutamate-fuelled mitochondrial reserve 
The majority of MØ research has been performed using cultured cell lines and/or 
in vitro-derived BMDM2. Accordingly, precise mechanisms of how cells meet metabolic 
demands in vivo remain unknown, making it critical to assess cell function in conjunction 
with tissue-niche metabolites. The peritoneum contains pTRMØ that are readily 
recovered without disruptive tissue digestion, limiting alterations of in vivo-
characteristics. We performed gas chromatography-time-of-flight metabolite analysis to 
determine metabolic differences between macrophage colony stimulating factor (M-
CSF)-derived BMDM, the standard model for macrophage functional analysis, and 
pTRMØ. Analysis revealed a stark contrast, with many metabolites having statistically 
significant differences (Two-way ANOVA post-tests p<0.05) (Supplementary Fig. 
1+Supplementary Table 1); however, unbiased ingenuity pathway analysis (IPA) described 
enrichment of tri-carboxylic acid (TCA) cycle-associated metabolites (Fig. 1a) and lower 
amino acids in pTRMØ compared to BMDM (Supplementary Fig. 1). Given these 
differences, we next compared their RNA expression. RNA-sequencing revealed expected 
contrasts in gene expression, although surprisingly, IPA analysis did not identify metabolic 
pathways as differentially regulated (Supplementary Fig. 2). However, there were 
statistically significant differences in many metabolic genes (Limma-Voom paired tests, 
p<0.05). This involved alternate expression of genes within the same metabolic pathways, 
including different isoform expression between the populations (Supplementary Fig. 3); 
 explaining the lack of IPA identification. Together, these data support that pTRMØ may 
have greater mitochondrial activity than BMDM and perhaps deplete amino acids to 
support this. To assess mitochondrial function, we quantified oxygen consumption rates 
(OCR) during mitochondrial stress tests (Fig. 1b,c). Interestingly, basal-OCR was 
comparable, however maximal mitochondrial capacity was greater in pTRMØ (Fig. 1c,d), 
despite similar mitochondrial quantification (Fig. 1e). Accordingly, we analysed 
mitochondrial volume in individual MØs (Supplementary videos 1-4). Mitochondrial 
morphology, volumes and numbers were heterogeneous (Supplementary Fig. 4a), 
although on average pTRMØ had fewer, but larger mitochondrial networks 
(Supplementary Fig. 4b), resulting in similar total mitochondrial volumes (Supplementary 
Fig. 4c). Collectively, this demonstrates that pTRMØ have similar mitochondrial volume 
but higher OXPHOS during metabolic stress, indicating greater mitochondrial efficiency23. 
Furthermore, pTRMØ exhibited higher extracellular acidification rates (ECAR), an 
indicator of glycolytic activity (Fig. 1b,d). 
OXPHOS is primarily fuelled from three sources: fatty acid oxidation, glycolysis, or 
glutaminolysis.  We sought to establish which fuels were used in maintenance of MØ 
mitochondrial function using inhibitors and fuel deprivation (Fig. 1b). Basal-OCRs of 
pTRMØ were resistant to nutrient stress, previously attributed to an internal pool of 
stored metabolites24. However, upon mitochondrial decoupling, the dependence of 
maximal OCR on metabolic pathways could be interrogated. Despite different origins, 
BMDM and pTRMØ display similar fuel dependence, although pTRMØ required less 
glucose-derived pyruvate (Fig. 1f,g). Together, these data demonstrate that pTRMØ have 
 approximately double the mitochondrial capacity of BMDM, which is primarily dependent 
on glutamine and fatty acids. 
Subsequently, we investigated whether peritoneal metabolites can support 
pTRMØ mitochondria. Indeed, peritoneal fluid augmented maximal OCR (Fig. 2a), 
demonstrating that peritoneal fuels support pTRMØ mitochondrial function. To identify 
specific fuels, we performed gas chromatography-time-of-flight metabolomic analysis on 
peritoneal fluid. Serum supplies metabolic fuels (such as glucose) from digestion to the 
body including the peritoneum. Therefore, to test whether specific metabolites might be 
enriched in the peritoneum compared to blood, we directly compared metabolite levels. 
Indeed, our analysis revealed many metabolites that were relatively enriched in serum or 
peritoneum (Supplementary Fig. 5+Supplementary Table 2). IPA analysis confirmed 
multiple pathways were distinct including fatty and amino acids, which were elevated in 
serum and peritoneum respectively (Supplementary Fig. 5). Among the most enriched 
amino acids in the peritoneum (Fig. 2b), we identified the neurotransmitter N-
acetylaspartate (NAA); a substrate for the pTRMØ-specific enzyme aspartoacyclase (Aspa 
gene)12. Moreover, glutamate, was greatly enriched in the peritoneum (Fig. 2b), although 
glutamine, the most abundant amino acid in serum, was comparable. Glutamate, can fuel 
glutaminolysis for anaplerotic replenishment of the TCA cycle (Fig. 1b), suggesting 
importance in control of pTRMØ OXPHOS. Glutamate, like glutamine, effectively fuelled 
maximal OCR in pTRMØ and synergized with glutamine to enhance mitochondrial 
function (Fig. 2c). Collectively, these data show that peritoneal fuels can support the 
substantial mitochondrial function in pTRMØ. Glutamate, together with other amino 
 acids such as glutamine, would enable maximum mitochondrial function in situ. Further, 
glutamine availability only limited decoupled OCR, demonstrating that pTRMØ become 
more dependent on glutaminolysis during stress. 
PTRMØ utilize glutaminolysis to maintain respiratory burst 
We investigated whether peritoneal-supplied, glutaminolysis-fuelled metabolism 
was important for a primary function of TRMØ – respiratory burst. We monitor 
respiratory burst to zymosan particles using OCR. These particles, but not soluble 
zymosan components or LPS, can initiate a protracted 4-6h respiratory burst in pTRMØ 
(Fig. 3a,b) demonstrating that particle uptake may be necessary. Other ligands, including 
uric acid crystals, N-Formylmethionyl-leucyl-phenylalanine (fMLF), Pam3CSK4, R848, 
apoptotic-thymocytes and Saccharomyces cerevisiae (S.cerevisiae) also trigger OCR 
increases (Supplementary Fig. 6a), although at lower magnitudes than zymosan. 
Therefore, we used zymosan-elicited OCR as tool to examine fuelling requirements for 
pTRMØ respiratory burst. Absence of glutamine or glucose did not affect zymosan 
phagocytosis in pTRMØ (Fig. 3c). However, zymosan-elicited OCR required glutamine and 
glucose to reach maximum intensity (Fig. 3d). The lower magnitude OCR increases seen 
with other ligands was also dependent on glutamine (Supplementary Fig. 6b). Glucose-
dependent increase in ECAR was also recorded in response to zymosan (Fig. 3d). Inhibition 
of glycolysis and the pentose phosphate pathway (PPP) using 2-deoxyglucose (2-DG) and 
dehydroepiandrosterone (DHEA) confirmed the requirement for glucose metabolism (Fig. 
3E), supporting that these pathways maintain the supply of ATP and/or NADPH25. Long 
 chain fatty acids were not a major requirement, and glutaminase inhibitors confirmed 
glutamine’s effeĐt was attributable to catabolism (Fig. 3f,g). Respiratory burst was also 
enhanced by glutamate, further supporting a requirement for anaplerosis (Fig. 3h). 
However, glutamate alone was unable to fully reconstitute the glutamine deprived 
respiratory burst, indicating different import mechanisms or efficiencies. 
Collectively these data demonstrate that respiratory burst in pTRMØ can be 
supported by locally enriched peritoneal glutamate and complemented by glutamine. 
Accordingly, the respiratory burst of human monocytes was also glutamine-dependent 
(Fig. 3i), indicating that interplay between metabolic programs and metabolic niches are 
not species-specific. 
Neutrophil respiratory burst is glutamine-independent  
The glutamine requirement for oxidative burst in pTRMØ was surprising, 
considering the glucose dependency of neutrophils25, another professional phagocyte. 
Respiratory burst of neutrophils was more acute than pTRMØ (Fig. 4a), despite similar 
levels of zymosan phagocytosis (Fig. 4b), indicating that neutrophils initiate, but don't 
sustain respiratory burst. Neutrophils, unlike pTRMØ, do not require glutamine to reach 
their peak burst, but were wholly dependent on glucose (Fig. 4c,d) through glycolysis (Fig. 
4E). An increase in glucose-dependent ECAR was also recorded (Fig. 4d). Collectively, 
these data demonstrate that in contrast to neutrophils, pTRMØ are pre-programmed to 
employ additional peritoneal fuels to augment respiratory burst with glutaminolysis.  
 PTRMØ respiratory burst is enhanced by CII metabolism 
Respiratory burst was originally appreciated as a rapid increase in oxygen 
consumption in neutrophils in response to pathogens, but was redefined as oxidase-
dependent free radical generation26, 27, 28. Unlike neutrophils29, pTRMØ have substantial 
basal OXPHOS (Fig. 5a) that could contribute to detected OCRs. Therefore, a 
mitochondrial stress test was performed during zymosan-induced pTRMØ respiratory 
burst to precisely dissect OCR and evaluate potential mitochondrial components. 
Unexpectedly, OCR during zymosan-induced respiratory burst was primarily attributable 
to increases in basal mitochondrial parameters (Fig. 5b) rather than additional oxidase 
activity. However, maximal mitochondrial capacity was unchanged (Fig. 5c), 
demonstrating that pTRMØ have the same mitochondrial capacity regardless of 
stimulation, but instead engage reserve mitochondrial capacity in response to zymosan 
challenge. Accordingly, a NOX inhibitor had little effect on zymosan-induced pTRMØ 
oxygen consumption, as opposed to neutrophil, which was ablated (Fig. 5d,e). 
Subsequently, we dissected this unique mechanism using specific inhibitors (Fig. 
5f) and utilized neutrophils, as a control to assess effects of mitochondrial inhibition on 
traditional NADPH oxidase-driven respiratory burst. As expected, complex I (CI) inhibition 
had no impact on neutrophil respiratory burst (Fig. 5g). Conversely, pTRMØ respiratory 
burst was highly dependent on respiratory chain complexes I, II and III (Fig. 5h). Inhibition 
of ATP synthase (linker of the respiratory chain to OXPHOS), had a less dramatic impact 
(Fig. 5h), suggesting the respiratory chain is decoupled during zymosan phagocytosis, 
which is supported by the increased proton leak (Fig. 5b). Unlike neutrophils, pTRMØ have 
 substantial basal-OCR, suggesting inhibition of vital OXPHOS components may affect 
phagocytosis itself. Indeed, reductions in pTRMØ phagocytosis were observed after CI or 
complex III (CIII) inhibition, but not CII (Fig. 5i). To control for this, electron transport 
complex inhibitors were used after zymosan uptake. The effect of these drugs on baseline 
OCR was compared to those recorded 90 min post-zymosan (Fig. 5j). CI inhibition had 
similar effects pre-and post-zymosan, indicating that CI function is necessary both before 
and during respiratory burst. Remarkably, CII inhibition did not substantially affect basal 
mitochondrial OCR, but drastically reduced the zymosan-induced OCR, demonstrating 
that CII engagement is enhanced during respiratory burst. Inhibition of CI or CIII had 
similar effects on basal-OCR. However, CIII inhibition during respiratory burst had a much 
greater impact, nearly eliminating both basal and zymosan-induced mitochondrial OCR. 
Together, these data strongly support a model wherein CI and CIII support basal pTRMØ 
OCR with little input from CII; however, during respiratory burst, CII engagement 
increases, supplying additional electrons to enhance OCR via CIII. This could affect ATP 
production (OXPHOS) or result in CIII-derived reactive oxygen species (ROS)30, 31, 32. It 
should be noted that, despite minimal OCR short-term effects from CII inhibition (<1h), 
long-term inhibition (5h) did suppress OCR (Fig. 5k); showing that CII is required for long-
term basal metabolism, but it does not directly contribute to measured basal-OCR. 
The increased utilization of CII and the requirement for glutaminolysis are often 
linked. The product of glutaminolysis, α-ketoglutarate, results in TCA-supplied succinate 
and glutamate can also pass through the GABA shunt to fuel CII (succinate 
dehydrogenase)33. Indeed, we found that glutaminolysis enhancement of zymosan-
 induced OCR is lost after CII inhibition (Fig. 5i), demonstrating that glutamine facilitates 
increased pTRMØ CII activity.  
Together these data demonstrate that pTRMØ are pre-programmed to exploit 
tissue-niche fuels to deliver a mitochondrially-driven respiratory burst through enhanced 
utilization of CII. 
PTRMØ metabolic changes are independent from TLR and NO 
Recently, Garaude et al. suggested that BMDM alter their mitochondrial 
supercomplex structures to favour CII activity after sensing bacterial RNA through Ticam1- 
and Myd88-dependent pathways34.  In contrast, decoupling the mitochondrial oxidative 
chain, part of the mitochondrial stress test, is sufficient for CII-dependent maximum 
pTRMØ mitochondrial capacity (Fig. 6a) and this dependency was unchanged after 
zymosan addition (Fig. 5c). Moreover, we recorded comparable levels of CII function 
before and after zymosan in pTRMØ (Fig. 6b). These data show, that unlike BMDM, which 
enhance their maximal mitochondrial capacity after activation via supercomplex 
changes34, zymosan-stimulated pTRMØ do not. 
Although we considered it unlikely that zymosan contains intact RNA, it does 
contain ligands for Toll receptors, which could stimulate similar pathways in pTRMØ.  
Thus, we tested whether increased CII-dependent OCR might be independent from Toll-
like pathways by comparing metabolic changes after zymosan in Tlr2?/?, MyD88?/? and 
Ticam1?/? pTRMØ. Zymosan-induced pTRMØ metabolic changes were unaffected in these 
mice (Fig. 6c,d), showing that CII enhancement can occur independently of toll-like 
 receptor/ bacterial RNA-sensing in these cells. Nitric oxide (NO) synthase (NOS) also 
consumes oxygen, produces free radicals, and has been shown to affect mitochondrial 
function35. However, respiratory burst was not perturbed in Nos2?/? pTRMØ (Fig. 6e). 
Taken together, these data demonstrate that although BMDM may require TLR-mediated 
RNA sensing for mitochondrial changes in response to bacteria, pTRMØ are poised to 
engage enhanced CII-mediated metabolism independently of TLR signalling. 
PTRMØ metabolic changes require protein kinase C 
Garaude et al. reported that the metabolic switch to CII was entirely dependent 
on NOX2 in BMDM34, conversely, we found that NOX2 inhibition had relatively minor 
effects on pTRMØ zymosan-induced oxygen consumption (Fig. 5e). However, 
pharmacological inhibition does not always completely eliminate activity, therefore we 
studied the burst in pTRMØ from mice lacking nuclear cytosolic factor-1 (NCF-1?/?), a vital 
NOX2 component. These cells showed no impairment in zymosan phagocytosis (Fig. 7a). 
However, respiratory burst was reduced, which is remarkable considering enhanced OCR 
was dependent on mitochondrial function, and that inhibition had little effect (Fig. 5e). 
Despite these reductions, we observed a similar pattern of increased OCR in response to 
zymosan, albeit at lower magnitude (Fig. 7b). This suggested some NOX2 activity is 
required for amplification of mitochondrial changes during respiratory burst, but is not 
required for engagement of CII. Indeed, enhanced oxygen consumption during the NCF-
1?/? pTRMØ respiratory burst was dependent on CII (Fig. 7c,d). 
 Enhancement of CII in zymosan-induced pTRMØ respiratory burst is independent 
of TLR signalling, therefore we investigated other mechanisms. protein kinase C (PKC) 
activation occurs downstream of dectin-1/Syk signalling, which are activated by zymosan 
in MØ36, 37. However, Dectin-1 is required for zymosan recognition in phagocytes36, so it 
may be required for engulfment as well as downstream signalling. To assess the role of 
PKC directly, we used phorbol-myristate-acetate (PMA). PMA does not interfere with 
dectin-1/Syk-mediated phagocytosis, but directly activates PKC. PMA treatment results in 
a short burst in OCR, the amplitude of which was dependent on NOX2 activity (Fig. 7b). 
However, PMA also enhanced mitochondrial function in NCF-1?/? pTRMØ (Fig. 7b), which 
was dependent on mitochondrial electron transport complexes (Fig. 7e), and elevated CII 
activity (Fig. 7f). We confirmed the requirement for PKC, through equivalent inhibition of 
zymosan or PMA-induced respiratory burst with a PKC inhibitor (Fig. 7f). The lower 
magnitude respiratory bursts seen with the addition of other ligands was, in the majority 
of cases, PKC-dependent (Supplementary Fig. 6c). Collectively, these data show that PKC 
activation can increase mitochondrial engagement of CII in pTRMØ independently of 
NOX2, however residual NOX2 activity may facilitate enhancement of these 
mitochondrial changes during phagocytosis. 
The pTRMØ metabolic switch supports the production of ROS  
CII-dependent OCR increases during respiratory burst could have consequences 
for cell functionality via free radical production, ATP synthesis, and/or NADPH recycling. 
ATP is required for lysosome acidification38 and organelle movement, while NADPH is 
 utilized for NOX2 activity and maintains cellular redox states. Therefore, we assessed ATP 
and NADPH after fuel deprivation in pTRMØ, conditions demonstrated to alter respiratory 
burst after zymosan. While ATP was drastically reduced after treatment with zymosan, 
absence of glucose or glutamine did not greatly affect ATP (Fig. 8a). NADPH was reduced 
after zymosan regardless of the availability of glucose or glutamine (Fig. 8a). This 
negligible effect of fuels on ATP and NADPH is distinct from patterns we observed in OCR 
(Fig. 3d), and contrasted with neutrophils which exhibited an absolute requirement for 
glucose in the maintenance of ATP, NADPH (Fig. 8b) and zymosan-induced OCR (Fig. 4c,d). 
The insignificant effects of fuel starvation on ATP and NADPH levels in pTRMØ 
demonstrates that these cells are metabolically plastic. Indeed, inhibition of metabolic 
pathways revealed that pTRMØ were not dependent on any singular pathway for 
maintenance of NADPH. However, we found substantial dependence on glycolysis rather 
that OXPHOS for ATP production (Fig. 8c).  Taken together, these data support the 
conclusion that pTRMØ have robust metabolic plasticity, which compensates for the lack 
of fuels, whereas neutrophils are dependent on glucose.  
An alternative mechanism for the involvement of mitochondria in respiratory 
burst is direct contribution to respiratory burst via mitochondrial superoxide and 
hydrogen peroxide. Zymosan non-specifically binds many mitochondrial targeted dyes 
(Fig. 9c,d). Therefore, we used PMA to assess mitochondrial capacity for producing 
superoxide. To limit NOX-derived ROS contamination, we used NCF-1?/? pTRMØ. PMA 
treatment increased mitochondrial superoxide in NCF-1?/? pTRMØ (Fig. 8d). Using a 
hydrogen peroxide probe, we tested whether localized superoxide production in the 
 mitochondria is indicative of general production of free radicals. Addition of zymosan to 
pTRMØ resulted in a hydrogen peroxide burst, which correlated with the respiratory burst 
measured by OCR. The hydrogen peroxide burst was sensitive to glutamine-deprivation 
or electron transport inhibition (Fig. 8e). These data demonstrate that complex-II 
dependent OCR correlates with ROS production, supporting that glutaminolysis supplies 
the electron transport chain to fuel pTRMØ mitochondrial ROS production during the 
response to zymosan.  
PTRMØ CII metabolism fine-tunes cytokine production 
MØ-derived cytokines are secreted in response to microbes or tissue damage and 
control inflammation1. TRMØ produce inflammatory mediators in response to 
S.cerevisiae, the microorganism from which zymosan is derived. Using two inhibitors, we 
measured specific effects of CII inhibition on S.cerevisiae-induced pTRMØ cytokine 
production. Interestingly, CII inhibition consistently reduced production of interleukin 
(IL)-10 and tumour necrosis factor (TNF), whereas IL-1? (mRNA and mature protein) and 
the neutrophil chemoattractant CXCL-1 (KC) were unaffected or inconsistently changed 
(Fig. 9a,b). Surprisingly, a different CII inhibitor, dimethylmalonate, had no effect on Il1b 
mRNA, but blocked ATP-induced secretion of IL-1? (Fig. 9a,b). Collectively, this shows that 
CII activity is required to fine-tune macrophage functional responses, which predictably 
will impact inflammatory resolution. 
 PTRMØ mitochondria are recruited to the cytotoxic phagosome 
We next investigated whether pTRMØ mitochondria associate with the 
phagolysosome, which would allow mitochondria to directly affect phagolysosome 
content, as has been reported in BMDM and monocytes39, 40. The pTRMØ mitochondrial 
network is vast and tubular (Fig. 9c, Supplementary videos 3-4) and ingestion of zymosan 
did not alter mitochondrial size significantly (Fig. 9f). However, after phagocytosis, 
zymosan is often situated near mitochondrial networks (Fig. 9c), which may represent 
mitochondrial recruitment to the phagolysosome39. Indeed, in some cases, as reported40, 
three-dimensional cupping of phagolysosomes with mitochondria was observed (Fig. 9d).  
Linear regression analysis confirmed enrichment of mitochondria toward the 
phagolysosome (Fig. 9e, R2=0.7162, Non-zero p<0.0001) making them well-situated to 
control the outcome of pTRMØ phagolysosome function. 
 We examined whether mitochondrial function was important for the killing of 
phagolysosome contents. Unexpectedly, addition of the CII inhibitor did not significantly 
reduce the killing of S.cerevisiae by pTRMØ (Fig. 9g), as has been recorded in the BMDM 
killing of bacteria34. This could be attributed to residual mitochondrial function after CII 
inhibition, which produces sufficient ROS to kill S.cerevisiae CIII is required for most 
pTRMØ ROS. Thus, in contrast to CII, CIII’s inhibition had a dramatic impact, even when 
added post S.cerevisiae to permit unadulterated uptake (Fig. 9h). This strongly suggested 
that reduced free radical production in the absence of CII activity is sufficient for 
antimicrobial function, whereas CIII inhibition may reduce mitochondrial function below 
the threshold required for effective antimicrobial activity. Collectively, these data suggest 
 that pTRMØ mitochondria move toward phagolysosomes where mitochondrial function 
contributes to the killing of ingested microbes.  
 Discussion 
Relatively little is known about TRMØ metabolism. Past research revealed that 
human leukocyte phagocytosis correlates with glutamine availability in the blood41, and 
that glutamine was important for interleukin production42, 43. Newsholme, Gordon and 
colleagues demonstrated that pTRMØ have an innate ability to use glutamine, but do not 
fully utilize this capacity during homeostasis24, 44. Therefore, we hypothesized that pTRMØ 
glutamine metabolism could be maximized during stress, and might be limited by 
glutamine availability in the tissue environment.  
In vitro-derived BMDM have been routinely used to study MØ functions, however 
TRMØ have different origins, are at the front-line of tissue defence. We hypothesized that 
examining these cells in context with their niche environment might reveal unique 
characteristics and/or mechanisms2. Based on this approach, we propose a model (Fig. 
10) where peritoneal-enriched fuels support metabolic repurposing of pTRMØ during 
stress. PTRMØ have considerable mitochondrial capacity fuelled by peritoneal glutamate/ 
glutamine, which supports CII-dependent repurposing of mitochondrial metabolism after 
phagocytosis and during stress. This metabolic switch is distinctive to a mechanism 
described in in vitro-derived BMDM34; can be initiated through PKC activation, and is 
required for pTRMØ ROS. Furthermore, we demonstrate that pTRMØ mitochondrial 
function is required for nominal cytokine expression and microbial killing.  
PTRMØ have increased TCA metabolites, larger mitochondrial networks and a 
greater OXPHOS capacity compared to in vitro-derived BMDM. RNA-seq analysis did not 
 uncover a causal basis for these differences, though it revealed opposite metabolic 
isoform expression patterns between these populations.  Differential utilization of 
metabolic transcriptional programs may underlie distinct mitochondrial phenotypes and 
function, although more study is needed to dissect these mechanisms. Alternatively, 
mitochondrial differences we describe may be the result of cell-specific reactions to non-
physiological oxygen and metabolic fuels in vitro or reflect different rates of proliferation. 
Mitochondrial network volumes are known to flux as the cell-cycle progresses45. As the 
proliferation rate of pTRMØ is very low3 compared to that of BMDM, we cannot rule out 
that ouƌ fiŶdiŶgs aƌe a ƌefleĐtioŶ of ͞ƌestiŶg͟ ǀs ͞pƌolifeƌatiǀe͟ ŵitoĐhoŶdƌia. Despite 
these caveats, when taken together with our metabolic profiling, these data show that in 
vitro-derived MØ are phenotypically and metabolically distinct to pTRMØ, suggesting 
their specialized metabolic programming is vital for cell-specific functions in unique 
environments in situ. 
We found the peritoneal metabolome to be distinct from serum, containing 
elevated amino acids, especially glutamate. Glutaŵate suppleŵeŶts glutaŵiŶe’s aďilitǇ to 
support pTRMØ mitochondrial function, demonstrating that glutamate production is 
limiting for pTRMØ metabolism in situ. The peritoneal metabolome also supports the 
proposed role of Aspa for pTRMØ survival12, by demonstrating that, compared to serum, 
the peritoneum is enriched with the Aspa substrate NAA. Thus, we now know of two 
examples where the niche environment provides factors required to specifically control 
pTRMØ phenotype and function. Interestingly glutamate is also a neurotransmitter. The 
source of peritoneal glutamate and NAA is unknown, although they may be released from 
 neurons and/or the gut micobiome46. Regardless, substantial presence of glutamate and 
NAA in the peritoneum is consistent with the known interplay of parasympathetic nerve 
function, gut physiology, and inflammation. 
We find that zymosan-induced pTRMØ respiratory burst is glucose-dependent, 
fatty acid-independent and required glutaminolysis, a metabolic pathway supported by 
peritoneal enriched glutamate. Surprisingly, zymosan-induced increases in OCR were 
attributable to increases in mitochondrial function. This explains the glutaminolysis 
requirement and it demonstrates that pTRMØ respiratory burst is fundamentally 
different from that of neutrophils, where increases in OCR can be entirely attributed to 
NOX activity, which requires glucose-fuelled maintenance of NADPH25. In pTRMØ, 
respiratory burst was not dependent on opsonisation and TLR2 was not required, but 
other receptors such as dectin-1 may be important36, 47, as both PMA and zymosan 
initiated mitochondrial-dependent respiratory bursts that were PKC-dependent. 
Interestingly, pTRMØ respiratory burst was accompanied by a burst in ECAR, suggesting 
that enhanced glycolysis may also be important. likely to supply additional ATP required 
for cell activation, which is consistent with the glycolytic-dependency of ATP production 
(Fig. 8c).  
The metabolic reprograming toward increased CII metabolism in pTRMØ we 
describe was not dependent on live bacterial sensing, as in BMDM34. Rather our data 
suggest that pTRMØ are metabolically poised to switch toward increased CII activity in 
situ. A priming event, such as sensing of the microbiome48, may be required for this in 
vivo. Such signalling is absent in cultured BMDM, but could be triggered via TLR-sensing 
 of live bacteria in vitro34. We demonstrate that pTRMØ enhancement of complex II 
activity does not require the NOX2 component NCF-1, despite a reduced amplitude in the 
absence of NCF-1. Notably, we find distinct differences between biochemical suppression 
of NOX2 and genetic ablation; the former having little effect while the latter effectively 
reduces burst. This seemingly paradoxical finding suggests that other cellular oxidases 
could specifically allow for the shift in mitochondrial function in the absence of NCF-1, 
while NOX2 may amplify burst via positive feedback, or be needed for a priming event in 
vivo that is not effectively inhibited pharmacologically. Such a model is supported by 
examples of NOX2 activating other oxidases and facilitating the generation of 
mitochondrial ROS30, 49. It is likely that glucose is required for PPP-fuelling of NOX2, as in 
the absence of glucose, but presence of glutamine, there is a reduced zymosan-induced 
OCR enhancement. Therefore, we propose that pTRMØ use glucose to activate NOX2 and 
maintain ATP, however the increased oxygen consumption is derived from NOX2-
amplification of mitochondrial function and fuelling from glutamine, rather than NOX2 
activity itself. Incidentally, we detected glutamine- and PKC-dependent increases in OCR 
from other ligands. However, these were of much lower magnitude than zymosan- or 
PMA-induced OCR. This could be attributed to a lack of NOX engagement, but could also 
indicate lower PKC activation or reduced uptake/binding of ligands. 
Respiratory burst was not detected in BMDM, despite similar rates of zymosan 
uptake (Supplementary Fig. 7), perhaps due to long-term suppressive effects of 
exogenous M-CSF on NOX2 components in BMDM50 or other downstream signalling 
mechanisms. Accordingly, cultured human monocytes also undergo a glutaminolysis-
 dependent respiratory burst, but only after interferon gamma pre-treatment to maintain 
NOX expression in vitro51. Thus, the respiratory burst enhancement through 
glutaminolysis we describe is not organism restricted, but may require NOX for optimum 
effectiveness. 
Respiratory burst H2O2 production in pTRMØ may be supported by mitochondrial 
superoxide via CIII30, 32, or the NOX-fuel NADPH via mitochondrial shuttles52, 53. Yet, we 
find that NADPH levels did not correlate with OCR changes, suggesting that mitochondrial 
ROS is responsible for glutaminolysis-enhanced H2O2. The near total sensitivity of 
zymosan-induced pTRMØ ROS to antimycin A is consistent with electron leak from CIII, 
rather than reported reverse electron transport from CII to CI54. We find that pTRMØ do 
not require CII to maintain their basal-OCR short-term, but increase their dependence on 
CII after phagocytosis. In fact, OXPHOS through CI does not require the full TCA cycle or 
CII, but purely requires NADH production that can be supplied by mitochondrial 
shuttles55. Inhibition of OCR after long-term CII inhibition is likely attributable to a build-
up of TCA metabolites which could ultimately inhibit NADH availability and subsequently 
affect CI activity. 
In addition to effects on respiratory burst, the switch toward increased CII activity 
in pTRMØ was also required for optimal cytokine secretion. Interestingly, ATP-induced IL-
1? secretion was reduced after treatment with dimethylmalonate but not by atpenin A5 
(CII inhibitors), while TNF and IL-10 were suppressed by both. Unlike atpenin A5, 
dimethylmalonate is a competitive inhibitor, which could affect succinate transporters 
and succinylation reactions.  It is also known to inhibit citrate synthase56 and all these 
 processes have been implicated in regulation of IL-1? making its effects difficult to 
interpret54.  Additionally, these inhibitors are likely to alter ROS, a signal known to activate 
the inflammasome and drive cytokine expression54, 57. NO production is another possible 
explanation for effects on inflammatory pathways.  We have previously shown that LPS 
drives NO production which directly suppresses MØ OXPHOS in BMDM35, reportedly by 
the suppression of mitochondrial complexes58. Therefore, inhibition of CII in BMDM could 
affect many factors, including NO production or its effect. However, pTRMØ stimulated 
with zymosan or S.cerevisiae do not produce appreciable NO (Supplementary Fig. 8), 
which is perhaps related to high arginase expression11 known to inhibit NOS59. Thus, 
unlike BMDM, pTRMØ metabolic control in situ is likely to be largely independent of NO, 
which will affect the outcome of cell activation and inflammation. 
Consistent with a role in respiratory burst, we found that pTRMØ recruit 
mitochondria toward phagolysosomes as has been shown in BMDM39, 40, 60, the latter 
dependent on TLR signalling. Interestingly, mitochondrial recruitment to zymosan-
phagolysosomes was maintained in Tlr2?/? pTRMØ (Supplementary Fig. 9), confirming 
their predisposition for response. Complete inhibition of mitochondrial function and 
subsequent ROS production using a CIII inhibitor impaired pTRMØ killing of microbes. It 
has been suggested that ROS in neutrophils primarily activates granule enzymes rather 
than directly killing microbes61. Given that ROS production is lower in MØ than 
neutrophils, it is unlikely that ROS production from MØ directly kills microbes, but rather, 
as with neutrophils, acts as a secondary messenger. Regardless, we find that peritoneal 
 metabolites which fuel pTRMØ mitochondrial function are important in the response to 
and the killing of microbes. 
In summary, for the first time, we examine TRMØ metabolic requirements with 
consideration of the corresponding tissue-niche environment. We demonstrate that 
pTRMØ are uniquely poised to utilize tissue-niche fuels to defend against microbial 
challenge. Further understanding of the metabolic requirements of effector cells in their 
unique tissue-niches will have meaningful impacts on our approach to treating disease in 




All reagents were from Sigma unless otherwise stated. Specific kits and linked reagents 
are described below. Non-canonical reagents are listed here: 
Rotenone, dehydroepiandrosterone (DHEA), thenoyltrifluoroacetone (TTFA), antimycin 
A, 2-deoxyglucose (2-DG), oligomycin, glutamate (pH 7.4 with NaOH), zymosan particles 
from Saccharomyces cerevisiae (including pHrodo, Thermo-Fisher), Yeast from 
Saccharomyces cerevisiae, LPS (lipopolysaccharide), luminol, DTAC 
(Dodecyltrimethylammonium chloride), Accutase, diazo-oxo-norleucine (DON), bis-
phenylacetamido-thiadiazolyl-ethyl sulfide (BPTES), atpenin A5 (Cayman chemicals), 
dimethyl malonate, UK-5099, etomoxir, phorbol-myristate-acetate (PMA), mitotracker 
red CMX-Ros (Thermo-Fisher), all-trans retinoic acid, M-CSF (Peprotech), VAS-2870, 
Sotrastaurin (Cayman chemicals), N-Formylmethionyl-leucyl-phenylalanine (fMLF), 
Pam3CSK4 (Invivogen), uric acid crystals, R848 (Invivogen), 4',6-Diamidino-2-Phenylindole 
(DAPI, Thermo-Fisher), Hoescht 33342 (Thermo-Fisher), 2-mercaptoethanol. 
Mice 
 Mice were on the C57BL/6 background and maintained in the Frederick National 
Laboratory Core Breeding Specific Pathogen Free Facility. NOX2 deficient NCF-1-/- 
(Ncf1?/?) mice62 were a kind gift from Dr. Steven Holland (National Institute of Allergies 
and Infectious Diseases, Bethesda, USA). Nos2-/- mice63 were a generous gift from Dr. 
Victor Laubach (University of Virginia). Myd88-/- mice64 were a gift from Dr. Giorgio 
Trinchieri, National Cancer Institute (NCI), Bethesda. Ticam1-/- mice were backcrossed 
onto the C57BL/6 background in our core facility65. Animal care was provided in 
aĐĐoƌdaŶĐe ǁith the pƌoĐeduƌes iŶ, ͞ A Guide foƌ the Caƌe aŶd Use of LaďoƌatoƌǇ AŶiŵals͟. 
Ethical approval for the animal experiments detailed in this manuscript was received from 
the Institutional Animal Care and Use Committee (Permit Number: 000386) at the 
National Cancer Institute-Frederick. Experiments were carried out on a mixture of male 
and female mice between 6 and 16 weeks of age. 
Primary cell preparation and purification 
Bone marrow leukocytes66 and peritoneal cells11 were isolated as previously 
described. Briefly, for peritoneal cells, the peritoneum of a mouse was lavaged with 5-
10ml phosphate buffered saline (PBS) using a 21-G needle. For bone marrow leukocytes, 
bone marrow was flushed out of trimmed leg bones using PBS and a 25-G needle. Red 
blood cells were lysed before cell culture. BMDM were differentiated from these cells and 
maintained using 20Ŷg/μl ƌeĐoŵďiŶaŶt ŵouse M-CSF as previously described66.  
For magnetic purification of primary cell populations: Cells were blocked with 
4μg/ŵl α-FĐγIII ;Ϯ.ϰGϮ, iŶ houseͿ iŶ ǁash ďuffeƌ PBS with 5mM 
 ethylenediaminetetraacetic acid (EDTA), 0.5% bovine serum albumin (BSA)) for 5min on 
ice, before addition of 20μg/ŵl α-Ly-6G-Biotin (1A8, Biolegend) to label neutrophils or 
20μg/ŵl α-F4/80-Biotin (BM8, Biolegend) to label pTRMØ for 30min on ice. Cells were 
then magnetically sorted with streptavidin micro-beads and LS columns as per 
manufactures instructions (Miltenyi Biotec), with an additional wash of 3 ml complete 
media (DulďeĐĐo’s ŵiŶiŵal esseŶtial ŵedia ;DMEM) with no pyruvate, 10 % fetal calf 
serum (FCS), 0.2units/ml penicillin, 100µg/ml streptomycin, 2mM L-glutamine, 25mM 
glucose) (Thermo-Fisher) for pTRMØ, or Seahorse media (Seahorse Bioscience) for 
neutrophils to remove EDTA, before elution of the positive selection in complete media 
or Seahorse media. Purities were typically 90-95% for neutrophils and 85-90% purity for 
pTRMØ, with the major peritoneal contaminant primarily being F4/80+ eosinophils.  
Human monocytes were obtained by gently adding 35ml blood to 15ml 
Histopaque (Ficoll) in a 50ml centrifuge tube. The tube was centrifuged for 30min at 600xg 
at room temperature. The peripheral blood mononuclear cell (PBMC) layer was 
removed to a centrifuge tube and re-suspended to 50ml with cold PBS (+2mM EDTA). 
This was again centrifuged for 5min at 600xg and the supernatant removed, the cells were 
washed 2 more times with PBS (+2mM EDTA). The Percol kit (GE Healthcare, 17-0891-01) 
was used to purify monocytes. Briefly, PBMCs were re-suspended in 5ml of solution A and 
this solution gently layered into a 15ml centrifuge tube containing a 54:47 mixture of 
solution A to solution B. The tubes were centrifuged for 30min at 1000xg, and the 
monocyte band removed, re-suspended in complete media and counted. Human blood 
was obtained from healthy volunteers, who were recruited through the National Cancer 
 Institute-Frederick Research Donor Program and provided written informed consent. All 
users of human materials were approved and appropriately trained. 
Extracellular flux analysis 
For neutrophil adherence, wells of an extracellular flux (XF) tissue culture plate 
were treated with Cell-Tak solutioŶ as peƌ ŵaŶufaĐtuƌeƌ’s iŶstƌuĐtioŶs ;CoƌŶiŶgͿ, however 
this was found to be unnecessary for adherence. Magnetically sorted pTRMØ were 
seeded at 0.5–1.0×106 (24-well) or 0.25×106 cells per well (96-well) in complete media 
(+0.5?M retinoic acid, +20ng/ml M-CSF) and incubated for 1.5-2h. The media was 
removed and replaced with Seahorse assay media with 2mM glutamine and 25mM 
Glucose (+0.5?M retinoic acid, +20ng/ml M-CSF) unless stated. Magnetically sorted 
neutrophils (1.0×106 cells per well, 24-well) in Seahorse assay media were also added to 
the Seahorse plate. The neutrophils were centrifuged to the bottom of the well at the 
lowest acceleration to 45×g followed by natural deceleration. Fully differentiated BMDM 
were removed from plates with a 10min incubation of accutase solution (37?C) and firm 
washing. Cells were centrifuged for 5min at 350xg, the supernatant removed and the cells 
re-suspended in Seahorse media containing 20ng/ml M-CSF, before plating for seahorse 
analysis: 100,000 cells for 96-well, 400,000 cells for 24-well. Human monocytes (above) 
were cultured for 48h at 2-million cells/ml in the presence of recombinant human M-CSF 
(50ng/ml) and interferon-? (10ng/ml). Monocytes were removed from plates like BMDM 
above, with the exceptions, that recombinant human M-CSF (50ng/ml) and interferon-? 
(10ng/ml) were added to the Seahorse media and cells were plated in the same 
 concentrations as pTRMØ. The plates containing cells were incubated for 1h at 37°C with 
no CO2. XF analysis was performed at 37°C with no CO2 using the XF-24 or XF-96 analyzer 
(Seahorse Bioscience) as per ŵaŶufaĐtuƌeƌ’s iŶstƌuĐtioŶs. Poƌt additioŶs aŶd tiŵes ǁeƌe 
used as indicated in the figures. Lavaged media was also used to replace media on 
pTRMØ, briefly, 0.5ml of Seahorse XF base media (no glucose or glutamine) was used to 
peritoneal lavage mice, with extra mixing. This lavage media was centrifuged at 500xg for 
10min, to remove cells, the supernatant removed and added to an Amicon 3kD centrifugal 
filter (Millipore). This was centrifuged at 3000xg for 60min, to remove large proteins. 
For apoptotic thymocytes: Thymuses were extracted and mechanically dissociated 
in complete RPMI media. Cells were re-suspended and counted in complete media. 
Thymocytes were seeded in 6-well plates (10x106 peƌ ǁellͿ ǁith deǆaŵethasoŶe ;ϭμMͿ 
for 3h. Cell were extracted from plates and washed three times in seahorse base media 
before re-counting and loading into injection ports (500,000 cell per well). Cells were 
additionally labelled using the PE Annexin V Apoptosis Detection kit (Becton Dickinson) as 
peƌ ŵaŶufaĐtuƌeƌ’s iŶstƌuĐtioŶs. OŶ aǀeƌage apoptosis ǁas ƌeĐoƌded as 20-40% exposure 
of phosphatidylserine with <10% dead cells. 
Flow cytometry 
For zymosan uptake: pHrodo zymosan particles (50?g/ml) was added to cells for 
ϭh oƌ ŵito“OX Red ;Ϯ.ϱμMͿ ǁas added to Đells foƌ ϮϬŵiŶ. Cells were washed with PBS and 
detached from culture plates using Accutase treatment at 37°C for 15min, before 
thorough pipetting. Cells were transferred to flow cytometry tubes and analysed by a BD 
 LSRII or BD Fortessa flow cytometer for fluorescent analysis. Doublets and debris were 
gates out before quantification of median fluorescent intensities with FlowJo (FlowJo, 
LLC). 
For apoptosis detection: Cells were transferred to flow cytometry tubes and 
analysed by a BD LSRII flow cytometer. Doublets were gates out before evaluation of % 
Annexin V+ 7AAD- (apoptotic) and % Annexin V+ 7AAD+ (dead) with FlowJo (FlowJo, LLC) 
(Supplementary Fig. 10). 
For purity checks: α-F4/80-Pacific blue/ Alexa Fluor 647 (BM8, Biolegend) or α-
CD11b allophycocyanin-Cy7 (M1/70, Becton Dickinson) were used for pTRMØ, and α-Ly-
6G (1A8, Biolegend) or CD11b allophycocyanin-Cy7 was used for bone marrow 
neutrophils (Supplementary Fig. 10). 
Real time polymerase chain reaction and RNA sequencing 
For real-time polymerase chain reaction: Atpenin A5 or dimethylmalonate were 
added 15min before 50?g/ml serum-opsonized (15-min serum opsonization at 37?C) 
S.cerevisiae to 600,000 pTRMØ in wells of a 48-well plate (final volume 250?l). The plate 
was incubated for 24h before RNA was extracted using the High-Pure RNA isolation kit 
(Roche, 11828665001Ϳ, as peƌ ŵaŶufaĐtuƌeƌ’s iŶstƌuĐtioŶs ;ǁith the additioŶ that Ϯ-
mercaptoethanol (1% v/v) was added to the lysis buffer). The High-Capacity cDNA Reverse 
Transcription kit (Thermo-Fisher, 4368813Ϳ ǁas used as peƌ ŵaŶufaĐtuƌeƌ’s guideliŶes to 
generate cDNA from the RNA. Real-time PCR was performed on an Applied Biosystems 
7300 using Eagle Taq (Roche) reagent and TaqMan gene expression probes: Hprt 
 (Mm01545399_m1), IL-1b (Mm00434228_m1) (Thermo-Fisher). Values are expressed as 
relative expression using the ??Ct method: IL-1b cycle threshold number (Ct) minus Hprt 
Ct = ?Ct, minus control sample ?Ct = ??Ct, relative expression considering the doubling 
per cycle of PCR = 2^-??Ct.  
For RNA-sequencing: RNA was taken from 1?106 naïve BMDM and pTRMØ using 
the method above. RNA quality was assessed using Agilent BioAnalyzer Nano chips and 
the RNA Integrity Number (RIN) algorithm. The RIN number was 8.3, 10, 10 and 10 for two 
pTRMØ and two BMDM samples respectively. RNA-Seq libraries were constructed from 
1µg of RNA using the Illumina TruSeq Stranded mRNA library preparation kit (Illumina, 
CA). Sequencing was done on Illumina HiSeq 2500 sequencers, with two lanes of paired-
end 125bp reads generated per sample. Raw files were aligned to mouse genome (mm10) 
using STAR (v. 2.3.0)67. Normalization was performed using trimmed mean of end values 
(TMM)68 after filtering out the genes that have 5 raw counts or less and were not shared 
by at least one sample. The Limma-Voom69 paired test was used to obtain fold values. 
Luminescence assays 
Magnetically sorted pTRMØ were seeded at 0.2–0.4×106 cells per well of a 96-well 
luminescence plate in complete media and incubated for 2h at 37°C. The media was 
replaced with minimal media (DMEM with no pyruvate, no phenol red, no glucose, no 
glutamine, 0.2units/ml penicillin, 100µg/ml streptomycin) or Seahorse media (No 
Glutamax, no glucose, no glutamine). Neutrophils were then added to separate wells on 
the plate and cells were supplemented with ± Glucose (25mM) or ± L-glutamine (2mM), 
 or additional treatments as indicated (including 400µM luminol). The plate was incubated 
at 37°C for 30min, after which ±zymosan (50μg/ml) was added. For luminol 
measurements the plate was placed in a 96-well luminescence plate reader and 
luminescence readings were measured every 6min for 6h. Otherwise, cells were lysed in 
passive lysis buffer (Promega) or 0.1M NaOH with 0.5% DTAC for ATP or NADPH 
determination respectively. Relative ATP was determined using the ATP assay kit (Abcam/ 
Thermo-Fisher) and NADPH/NADP ratios determined using the NADPH-Glo assay kit 
;PƌoŵegaͿ as peƌ ŵaŶufaĐtuƌeƌ’s iŶstƌuĐtioŶs. 
Primary metabolite analysis 
Magnetically sorted pTRMØ or gently scraped cultured BMDM (5.0-7.5×106) were 
pelleted and snap-frozen in liquid nitrogen. A trypan blue dilution assay was used to 
determine the average fluid quantity in the peritoneum (Supplementary Fig. 11). This was 
deteƌŵiŶed to ďe ≈ϭϬϬμl. MiĐe ǁeƌe laǀaged thoƌoughlǇ ǁith ϯϬϬ μl of PB“ to giǀe a ≈ϰ× 
diluted lavage sample. Blood collected in serum tubes and lavage samples were 
centrifuged at 1200×g for 15min to remove cellular components. Serum was also diluted 
in PBS to give 4× diluted serum samples. Samples were further processed and analysed at 
the West Coast Metabolomic Center (University of California, Davis).  Briefly, samples 
were re-suspended with 1 ml of extraction buffer (37.5% degassed acetonitrile, 37.5% 
isopropanol and 20% water) at –20°C, centrifuged and decanted to complete dryness. 
Membrane lipids and triglycerides were removed with a wash in 50% acetonitrile in water. 
The extract was aliquoted into two equal portions and the supernatant dried again. 
 Internal standards C08-C30 fatty acid methyl esters were added and the sample 
derivatized by methoxyamine hydrochloride in pyridine and subsequently by N-methyl-
N-trimethylsilyltrifluoroacetamide for trimethylsilylation of acidic protons. Gas 
chromatography-time-of-flight analysis was performed by the Agilent GC6890/LECO 
Pegasus III mass spectrometer. Samples were additionally normalised using the sum of 
peak heights for all identified metabolites. 
Cytokine production and Saccharomyces cerevisiae killing 
For cytokine analysis: Atpenin A5 or dimethylmalonate were added 15min before 
50?g/ml serum-opsonized (15-min serum opsonization at 37?C) Saccharomyces 
cerevisiae (S.cerevisiae) to 600,000 pTRMØ in wells of a 48-well plate. The plate was 
incubated for 24h before supernatant removal. The BD cytometric bead array kit (558267) 
ǁas used to ƋuaŶtifǇ ĐǇtokiŶes iŶ supeƌŶataŶt, aŶd ǁas used as peƌ ŵaŶufaĐtuƌeƌ’s 
instructions. For killing quantification: S.cerevisiae was added to pre-cultured pTRMØ 
(described above) or empty wells in a 1:2 ratio. Antimycin A was added was added 30min 
after S.cerevisiae to avoid known defects in uptake. S.cerevisiae with or without pTRMØ 
were mixed with Triton-X100 (1% final) by pipetting and incubated for 5min. Dilutions in 
water (1:10, 1:50, 1:200 final) were plated (25?l) onto YPD-agar 9cm bacterial plates using 
L-shaped spreaders. Plates were incubated at 30°C for 48h before counting of colony 
numbers.  
 Confocal microscopy 
For figure 9: pTRMØ were pre-cultured in complete media (750,000 per 35mm 
dish, +0.5?M retinoic acid, +20ng/ml M-CSF) for 18h on glass-bottom culture dishes 
(MatTek, #0). pHrodo zymosan particles (50?g/ml) were added to cells for 1h and/or 
Mitotracker Red CMXRos (25nM) was added to cells for 20min. Cells were washed twice 
with PBS and fixed with 4% paraformaldehyde for 20min at room temperature. Cells were 
washed with PBS and 6-Diamidino-2-Phenylindole (DAPI, 125ng/ml) added. A Zeiss UV-
510 confocal microscope and 63x oil immersion objective lens was used to capture images 
using differential interference contrast, 405, 488 and 561nm laser paths (pinhole size = 1 
airy unit). 
For supplemental figures 4 and 7: pTRMØ (300,000 per 24-well, +0.5?M retinoic 
acid, +20ng/ml M-CSF) or BMDM (150,000 per 24-well, +20ng/ml M-CSF) were seeded for 
18h on glass-bottom culture dishes (CellVis, #1.5). pHrodo zymosan particles (50?g/ml) 
were added to cells for 1h and/or Mitotracker Red CMXRos (25nM) was added to cells for 
20min. Cells were washed twice with PBS and fixed with 4% paraformaldehyde for 20min 
at room temperature. Cells were washed with PBS and Hoescht 33342 (1?g/ml) added 
before further washing. A Leica TCS SP8 confocal microscope with Yokogawa CSUW1 
spinning disk and a 100x oil immersion objective lens was used to capture images using 
405, 488 and 561nm laser paths. 
Images were analysed using Fiji (ImageJ)70. For quantification of mitochondrial 
proximity to the phagolysosome: Mitotracker positive pixels were quantified at different 
 radial distances from fluorescent zymosan particles (up to 5?m) and data was expressed 
as percentage of total mitochondrial localization. The 3D objects counter71 was used to 
calculate approximate mitochondrial volumes, which is based on 65nm2 per pixel and a 
100nm z-step size, to give voxels of 6500nm3. 3D models visually fit the data well 
(Supplementary videos 1-4). 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism 6 & 7, and the tests used 
were Students t-tests, one-way and two-way ANOVAs with post-tests and linear 
regression, as are indicated in figure legends, all data are assumed normally distributed 
and were log transformed where appropriate before analysis.  * = P < 0.05, ** = P < 0.01, 
*** = P < 0.001. Ingenuity pathway analysis (IPA, Qiagen) was used on metabolomic 
datasets to identify differences in metabolite pathways. All error bars represent the 
mean± the standard error of the mean (SEM unless stated). 
Data availability 
The RNA-seq data discussed in this publication have been deposited in NCBI's 
Gene Expression Omnibus72 and are accessible through GEO Series accession number 
GSE104920:  https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE104920. The 
metabolomics data are attached as supplementary tables 1-2 and all other data are 
available from the authors upon request. 
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 Figure legends 
Figure 1. Peritoneal tissue-resident macrophages are highly oxidative and are fuelled by 
glutamine 
a) Heat-map showing the log10 difference from the average metabolite peak areas from 
Gas Chromatography-Mass Spectrometry, which are associated with the citric acid cycle 
from peritoneal tissue-resident macrophages (Res) and bone marrow-derived 
macrophages (BMDM). Data shows 3-6 independent samples per group analysed by two-
ǁaǇ ANOVA ;iŶteƌaĐtioŶ<Ϭ.ϬϬϬϭͿ ǁith “idak’s post-tests. b) Schematic showing a 
simplified metabolic pathway detailing readouts for extracellular acidification rate 
(ECAR), oxygen consumption rate (OCR) and drugs which inhibit these pathways, the red 
oval indicates the mitochondria. c) Graph showing representative Seahorse mitochondrial 
stƌess tests, O=oligoŵǇĐiŶ ;ϭ.ϮϲμMͿ, F=FCCP ;Ϭ.ϲϳ?M), R/AA=Rotenone (0.2?M) 
+antimycin A (1?M). d) Bar graphs showing quantified protein-normalized ECAR and 
mitochondrial OCR from stress tests in (c), combination of the two OCR parameters 
represents the maximum mitochondrial capacity. Data (n=3 separate wells per group) 
represents three experiments, OCR data were analysed by paired two-way ANOVA 
;iŶteƌaĐtioŶ p<Ϭ.ϬϬϬϭͿ ǁith “idak’s post-tests for the difference between Res and BMDM 
;ƌeseƌǀe/ ŵaǆiŵal ŵitoĐhoŶdƌial ĐapaĐitǇͿ oƌ ďǇ “tudeŶt’s t-test (ECAR). e) Bar graph 
depiĐtiŶg the ƌatio of ŵitoĐhoŶdƌial ϭϲs deoǆǇƌiďoŶuĐleiĐ aĐid ;DNAͿ ǀs β-actin DNA in 
thƌee iŶdepeŶdeŶt saŵples, data ǁas Ŷot sigŶifiĐaŶt ďǇ “tudeŶt’s t-test. f) Bar graph 
showing the drop in maximum decoupled mitochondrial OCR after addition of drugs or 
 withdrawal of fuels. Glucose dependence was assessed using 2-deoxyglucose (2-DG, 
100mM), pyruvate using UK-5099, a mitochondrial pyruvate transport inhibitor, long-
ĐhaiŶ fattǇ aĐids ďǇ etoŵoǆiƌ ;ϭϬϬμMͿ aŶd glutaŵiŶe ďǇ ϭh staƌǀatioŶ ďefoƌe 
reintroduction of glutamine (2mM) or control media. g) Stacked bar graph showing a 
breakdown of the effects of different metabolic fuels on maximum mitochondrial capacity 
from (f). Data (e) and (g) (n=at least 3 separate wells per group) represent at least two 
experiments, and were analysed by two-way ANOVA ((G) interaction p=0.02; (F) 
iŶteƌaĐtioŶ p=Ϭ.Ϭϱϲ, Đell p=Ϭ.Ϭϭϳ, fuel p<Ϭ.ϬϬϬϭͿ ǁith “idak’s post-tests.  All error bars 
denote mean?SEM.  
 Figure 2. Peritoneal tissue-resident macrophage mitochondria can be fuelled through 
abundant peritoneal glutamate 
a) Bar graph showing the effect of 5? diluted peritoneal fluid (by 1mM glucose media 
lavage) in comparison to 1mM glucose media on mitochondrial parameters in peritoneal 
tissue-resident macrophages (Res). Data were from one experiment (n=5-6 separate wells 
per group) and analysed by paired two-ǁaǇ ANOVA ;iŶteƌaĐtioŶ p<Ϭ.ϬϬϬϭͿ ǁith “idak’s 
post-tests. b) Heat-map showing the log10 difference from the average metabolite peak 
areas from Gas Chromatography-Mass Spectrometry analysis of the most enriched amino 
acids in peritoneal lavage fluid and the fatty acids in blood serum, glucose and glutamine 
act as a reference. Data shows 5 independent samples that were analysed by two-way 
ANOVA ;iŶteƌaĐtioŶ p<Ϭ.ϬϬϬϭͿ ǁith “idak’s post-tests. c) Stacked graph detailing the 
addition of glutamine (Q, 0.25mM) and glutamate (0.5mM) to peritoneal tissue-resident 
macrophages and resulting changes in mitochondrial parameters. Data are from the same 
experiment as (a), but increases in mitochondrial function after glutamate and Q 
represent 3 independent experiments, data were analysed by two-way ANOVA 
;iŶteƌaĐtioŶ p<Ϭ.ϬϬϬϭͿ, “idak’s post-tests are indicated within the bars for parameters vs 
1mM glucose and above representing the synergistic effect of glutamate and Q. All error 
bars denote mean?SEM.  
 Figure 3. Peritoneal tissue-resident macrophages enhance their respiratory burst with 
glutaminolysis 
a) Line graph showing oxygen consumption rate (OCR) in peritoneal tissue-resident 
macrophages ;ResͿ. Aƌƌoǁ=zǇŵosaŶ ;ϱϬμg/ŵlͿ, LP“ ;ϭϬϬŶg/ŵlͿ oƌ ĐoŶtƌol. b) OCR 
changes in Res with washed particle- or soluble-zymosan components. Data were 
analysed ďǇ “tudeŶt’s t-test. c) Quantification of Res uptake of pHrodo zymosan 
;ϱϬμg/ŵl,ϭhͿ. G=gluĐose ;ϮϱŵMͿ, Q=glutamine (2mM). Data was not significant by one-
ǁaǇ ANOVA ;p=Ϭ.ϬϳϱϲͿ ǁith TukeǇ’s post-tests. d) OCR or extracellular acidification rate 
(ECAR) vs time in Res. Cells were starved from glutamine (Q) and cultured ±glucose before 
addition of Q or control (grey arrow). Zymosan=black arrow. Peak burst is quantified in 
the chart and analysed by one-ǁaǇ ANOVA ;p<Ϭ.ϬϬϬϭͿ, sigŶifiĐaŶt TukeǇ’s post-tests for 
Q addition are shown. e) Graph showing the total oxygen consumption of Res after 
zymosan, quantified from OCR vs time (as in (d)), in the presence of 2-deoxyglucose (2-
DG, ϭϬϬŵMͿ, dehǇdƌoepiaŶdƌosteƌoŶe ;DHEA,ϭϬϬμMͿ oƌ ǀehiĐle. Data ǁeƌe analysed by 
“tudeŶt’s t-test. f) Graph showing the percentage oxygen consumption of Res after 
zǇŵosaŶ iŶ the pƌeseŶĐe of etoŵoǆiƌ ;ϱϬμMͿ oƌ ǀehiĐle. Data is a pool of two experiments 
(n=6-7) and was analysed by two-way ANOVA (Interaction p=0.376, etomoxir p=0.2588).  
g) Relative total oxygen consumption after zymosan of Res pre-treated with 
glutaminolysis inhibitors bis-phenylacetamido-thiadiazolyl-ethyl sulfide ;BPTE“, ϭϱμMͿ 
and diazo-oxo-norleucine (DON, 10mM), in the presence or absence of Q. Data were 
analysed by two-ǁaǇ ANOVA ;iŶteƌaĐtioŶ p=Ϭ.ϬϱϯϲͿ ǁith “idak’s post-tests. h) Total 
oxygen consumption after zymosan of Res in the presence or absence of Q (4mM) or 
 glutamate (4mM). Data were analysed by one-ǁaǇ ANOVA ;p<Ϭ.ϬϬϬϭͿ ǁith TukeǇ’s post-
tests. i) Human monocytes were pre-cultured for 48h with recombinant human M-CSF 
(50ng/ml) and interferon-? (10ng/ml). Oxygen consumption was quantified as in (d) and 
shows 6 separate wells per group pooled from two experiments, analysed by two-way 
ANOVA (interaction p = 0.1231), the *** depicts the significant effect of Q (p= 0.0009). 
Data (a-e,g-h) represent two experiments with at least 3 separate wells per group. All 
error bars denote mean?SEM. 
  
 Figure 4. Glutamine does not support neutrophil respiratory burst 
a) Line plot of OCR vs time in tissue-resident macrophages (Res) and bone marrow 
Ŷeutƌophils. Aƌƌoǁ iŶdiĐates the additioŶ of zǇŵosaŶ ;ϱϬμg/ŵlͿ. Data aƌe fƌom two 
separate experiments and represent at least 3 independent observations. b) Bar chart 
shoǁiŶg the ƋuaŶtifiĐatioŶ of pHƌodo zǇŵosaŶ ;ϱϬμg/ŵlͿ uptake. Data shoǁs ϯ sepaƌate 
samples per group, represents two independent experiments and was not significant by 
“tudeŶt’s t-test. c) Line plot showing OCR vs time in neutrophils in the absence of 
glutamine (Q) and presence or absence of glucose (25mM) for 90min before addition of 
Q (2mM) or control media (grey arrow). Zymosan=black arrow. d) Peak burst 
quantification of plots from (c) and ECAR plots from the data in (c). Data (c,d) represents 
at two independent experiments with 3 separate wells per group. Peak burst data were 
analysed by one-ǁaǇ ANOVA ;p=Ϭ.ϬϮϲϮͿ, TukeǇ’s post-tests for the addition of glutamine 
were not significant. e) Total oxygen consumptions were quantified by area under the 
curve of OCR vs time as seen in (c) in presence of 2-deoxyglucose (2-DG,100mM) or 
vehicle control. Data (n=at least 3 separate wells per group) represents two independent 
experiments and was analysed ďǇ “tudeŶt’s t-test. All error bars denote mean?SEM. 
 Figure 5. Peritoneal tissue-resident macrophages enhance mitochondrial function 
during respiratory burst through a glutaminolysis enhancement of complex II 
a) Peritoneal tissue-resident macrophage (Res) and neutrophil basal-OCR. Data shows at 
least 10 wells per group and represents three observations. b) Changes in mitochondrial 
paƌaŵeteƌs afteƌ zǇŵosaŶ ;ϱϬμg/ŵlͿ to Res. Data ;Ŷ=ϲ sepaƌate ǁells peƌ gƌoupͿ 
represents three experiments analysed by paired two-way ANOVA (interaction p<0.0001) 
ǁith “idak’s post-tests. c) The maximal mitochondrial capacity from (b). d) Graph showing 
the total oxygen consumption of neutrophils after zymosan, ±VAS-2870 (10?M). Data (9 
wells per group from three experiments) were analysed by two-way ANOVA (interaction 
p=0.8567), ***=the significant effect of VAS-2870 (p=0.0005). e) Oxygen consumption of 
Res as in (d). Data (6 wells per group from two experiments) were analysed by two-way 
ANOVA (interaction p=0.138), *=the significant effect of VAS-2870 (p= 0.0331). f) A 
simplified diagram of the electron transport chain (ETC). Inhibitors are shown in red. g) 
The effect of rotenone (200nM) on total oxygen consumption of neutrophils after 
zymosan. Data shows 3 wells per group and represents three experiments. h) The total 
oxygen consumption of Res after addition zymosan in the presence of the ETC inhibitors: 
oligoŵǇĐiŶ ;ϭ.ϮϲμMͿ, ƌoteŶoŶe ;ϮϬϬŶMͿ, theŶoǇltƌifluoƌoaĐetoŶe (TTFA,2mM), 
aŶtiŵǇĐiŶ A ;ϭμMͿ. Data shoǁs ϯ ǁells peƌ gƌoup, ƌepƌeseŶts tǁo eǆpeƌiŵeŶts aŶd ǁeƌe 
analysed by one-ǁaǇ ANOVA ;p<Ϭ.ϬϬϭͿ ǁith TukeǇ’s post-tests vs control. i) The effect of 
metabolic drugs (f) and 2-deoxyglucose(2-DG,100mM) on the uptake of pHrodo 
zǇŵosaŶ;ϱϬμg/ŵl,ϭhͿ. Data ǁeƌe analysed by one-ǁaǇ ANOVA ;p<Ϭ.ϬϬϭͿ ǁith TukeǇ’s 
post-tests vs control. j) Graph showing change in OCR after addition of indicated drugs (f) 
 aŶd atpeŶiŶ Aϱ ;ϭμMͿ. Post tƌeatŵeŶt ;PostͿ is ϵϬŵiŶ afteƌ zǇŵosaŶ, pƌe-treatment 
occurs before zymosan (Pre). Data shows 3 wells per group, represents at least two 
experiments and were analysed by two-ǁaǇ ANOVA ;iŶteƌaĐtioŶ p<Ϭ.ϬϬϬϭͿ ǁith “idak’s 
post-tests. k) The effect of a 5h atpenin treatment on OCR in Res. l) Graph showing total 
oxygen consumption of zymosan-induced Res after atpenin A5 ?glutamine. Data (6 
separate wells per group) is a pool of two experiments and was analysed by two-way 
ANOVA ;IŶteƌaĐtioŶ p=Ϭ.ϬϬϳϵͿ ǁith “idak’s post-tests. All error bars denote mean?SEM, 
except (c) which shows the median, data in a,c,g,k were analysed ďǇ “tudeŶt’s t-test. 
  
 Figure 6. The metabolic switch in peritoneal tissue-resident macrophages is 
independent of nitric oxide and TLR signalling 
a) Line graph showing relative changes in oxygen consumption rate (OCR) vs atpenin A5 
dose in peritoneal tissue-resident macrophages (Res). Data is from a single experiment 
(n=5-6 separate wells per group), but the difference between basal and maximal OCR 
changes represents at least 3. b) Line graph showing OCR vs time in Res. Cells were treated 
ǁith oƌ ǁithout zǇŵosaŶ ;ϱϬμg/ŵl, ϮhͿ ďefoƌe ŵetaďoliĐ fluǆ aŶalǇsis; Đells ǁeƌe 
permeablised with PMP and rotenone added, succinate was added at the grey arrow, and 
atpeŶiŶ Aϱ ;ϭμMͿ ǁas added at the black arrow. Data represents at least two independent 
experiments and shows 6 separate wells per group. Data (a,b) were analysed by paired 
two-ǁaǇ ANOVA ǁith “idak’s post-tests. c) Graph showing the increase in mitochondrial 
parameters from WT, MyD88-/- and Ticam1-/- Res calculated by comparing mock and 
zymosan treated samples as seen in figure 5b. Data shows n=6 separate wells per group 
from one experiment. d) Graph showing OCR vs time, zymosan was added to wild-type 
(WT) and Tlr2-/- Res at the arrow indicated. Data shows n=5 separate wells per group from 
one experiment. e) Graph showing OCR vs time, zymosan was added to wild-type (WT) 
and Nos2-/- Res at the arrow indicated. Data in the left panel shows n=5 separate wells 
per group pooled from two experiments. All error bars denote mean?SEM.  
 Figure 7. The metabolic enhancement in peritoneal tissue-resident macrophages occurs 
independently of NOX2, but can be initiated with activation of protein kinase C 
a) Peritoneal tissue-resident macrophage (Res) uptake of pHƌodo zǇŵosaŶ ;ϱϬμg/ŵlͿ 
from NCF-1-/- and WT mice. Data shows 3 separate wells per group and was not 
sigŶifiĐaŶtlǇ diffeƌeŶt ďǇ “tudeŶt’s t-test. b) OCR changes in WT and NCF-1-/- Res after 
addition of zymosan or phorbol-myristate-aĐetate ;PMA, ϭμMͿ at the indicated arrow. 
The far-right line graph shows an expanded view of NCF-1-/- data from the middle plot. 
Data from the WT shows n=3 separate wells per group from one experiment, while the 
NCF-1-/- shows n=5 per group from two separate experiments. Both are representative of 
at least 3 independent experiments. c) The relative total oxygen consumption after 
addition of atpenin A5 or vehicle control in NCF-1-/- Res. Data (n=5 separate wells per 
group) represents two independent experiments and was analysed ďǇ “tudeŶt’s t-test. d) 
Graph showing change in OCR after addition of atpenin A5 or vehicle control. Post 
treatment (Post) is applied 90min after zymosan addition, pre-treatment occurs before, 
in the absence of zymosan (Pre). Data (n=10-12 separate wells per group) is poled from 
two independent experiments and were analysed by two-way ANOVA (interaction 
p<Ϭ.ϬϬϬϭͿ ǁith “idak’s post-tests. e) Quantification of the total oxygen consumption after 
addition of PMA in the presence of the indicated inhibitors (rotenone=200nM). Data (n=3-
6 separate wells per group) represents two independent experiments and were analysed 
by one-ǁaǇ ANOVA ;p<Ϭ.ϬϬϬϭͿ ǁith TukeǇ’s post-tests. f) Graph showing change in OCR 
after addition of the indicated drugs. Post treatment (Post) is applied 40min after PMA 
addition, pre-treatment occurs before, in the absence of PMA (Pre). Data (n=5-6 separate 
 wells per group) represent two independent experiments. Data were analysed by two-
ǁaǇ ANOVA ;iŶteƌaĐtioŶ p<Ϭ.ϬϬϬϭͿ ǁith iŶdiĐated “idak’s post-tests. g) The protein kinase 
C inhibitor sotrastaurin (5?M) or control were added to Res 30min before addition of 
respiratory burst stimulants PMA or zymosan, data is quantified as relative total oxygen 
consumed post burst stimulants. Data (n=5 separate wells per group) represent two 
independent experiments, analysed by two-way ANOVA (interaction p=0.6854, 
sotƌastauƌiŶ p<Ϭ.ϬϬϬϭͿ ǁith iŶdiĐated “idak’s post-tests. All error bars denote 
mean?SEM.  
 Figure 8: The electron transport chain is required for nominal reactive oxygen species 
production in peritoneal tissue-resident macrophages 
a) Bar graphs showing ATP and NADPH assays of peritoneal tissue-resident macrophages 
(Res). Cells were starved of glutamine (2mM) and/or glucose (25mM) 1h before addition 
of zǇŵosaŶ ;ϱϬμg/ŵlͿ oƌ ĐoŶtƌol, eǆtƌaĐts ǁeƌe takeŶ afteƌ Ϯh. Data ǁeƌe analysed by 
two-way ANOVA. For ATP, interaction p=0.16, effects of zymosan or fuel p<0.0001. For 
NADPH ratio, interaction p=0.041. b) Bar graphs showing ATP and NADPH assays of 
neutrophils. Cells were treated as in (a), data were analysed by two-way ANOVA with 
“idak’s post-tests for glutamine addition. For ATP, interaction p=0.21, zymosan p=0.15, 
fuel p<0.0001. For NADPH ratio, interaction p=0.85, zymosan p=0.56, fuel p<0.0001. c) 
Bar graphs showing ATP and NADPH assays of Res. Cells were treated with inhibitors 
ϯϬŵiŶ ďefoƌe additioŶ of zǇŵosaŶ as iŶ ;AͿ. OligoŵǇĐiŶ ;ϭ.ϮϲμMͿ, ƌoteŶoŶe ;ϮϬϬŶMͿ, 
theŶoǇltƌifluoƌoaĐetoŶe ;TTFA, ϮŵMͿ, aŶtiŵǇĐiŶ A ;ϭμMͿ, dehǇdƌoepiaŶdƌosteƌoŶe 
;DHEA, ϭϬϬμMͿ, Ϯ-deoxyglucose (2-DG, 100mM). Data were analysed by two-way ANOVA 
with Sidak’s post-tests vs control. For ATP, interaction p=0.47, zymosan or drug were 
p<0.0001. For NADPH ratio, interaction p=0.036. Data (a-c) represent at least two 
independent experiments and show 3-4 separate wells per group. d) Bar chart showing 
the median fluorescent intensity (MFI) of mitoSOX dye in NCF-1-/- Res treated with 
phorbol-myristate-aĐetate ;PMA, ϭμMͿ oƌ ĐoŶtƌol. Data ;Ŷ=ϰ sepaƌate ǁells peƌ gƌoupͿ 
represents two independent experiments and were analysed ďǇ “tudeŶt’s t-test. e) Line 
graph (left) showing luminol luminescence against time in Res treated with zymosan 1min 
before time 0. Bar chart (right) showing quantification of the area under the curve 
 luminescence from the line graph in the presence of the indicated inhibitors (as in (b) 
+atpeŶiŶ Aϱ ;ϭμMͿͿ. Data ;Ŷ=ϰ-6 separate wells per group) were combined from two 
separate experiments, each treatment result is representative of at least two 
independent experiments. Data were analysed by one-ǁaǇ ANOVA ǁith TukeǇ’s post-
tests vs the matched control. All error bars denote mean?SEM. 
  
 Figure 9: The mitochondrial electron transport chain is required for antimicrobial 
function in peritoneal tissue-resident macrophages 
a) Quantification of cytokines from peritoneal tissue-resident macrophage (Res) 
supernatant 24h after Saccharomyces cerevisiae (S.cerevisiae) ;ϱϬμg/ŵlͿ ?dimethyl 
malonate (DMM,10mM) or ?atpenin A5 (1?M). The far-right panel shows IL-1? after 1h 
post-stimulation with adenosine triphosphate (ATP,3mM), 23h after S.cerevisiae. Data 
(n=4 separate wells per group) represents 2 independent experiments. For TNF, IL-10 and 
KC, data were analysed by one-ǁaǇ ANOVA ǁith DuŶŶett’s post-tests; for IL-1?, data was 
analysed by two-ǁaǇ ANOVA ǁith “idak’s post-tests vs vehicle control or vs no ATP as 
indicated (interaction p<0.0001, ATP p<0.0001, complex II p<0.0001). Error 
bars=mean?SEM. b) Relative expression of Il1b RNA from samples in (a). c) 
Representative photographs of Res. In (c,d), zymosan-AleǆaFluoƌϰϴϴ ;ϱμg/ŵlͿ aƌe gƌeeŶ, 
mitochondria labelled with MitotrackerRed CMXRos (25nM) are red, while the nuclei are 
labelled blue with 6-Diamidino-2-Phenylindole (DAPI,125ng/ml). The yellow box denotes 
mitochondria surrounding zymosan. Zymosan cores can be seen with non-specific 
MitotrackerRed fluorescence. d) A characteristic z-stack showing mitochondria 
surrounding the phagolysosome. The yellow numbers denote distance from coverslip. e) 
Quantification of the number of MitotrackerRed positive pixels expressed as percentage 
of total (termed mitochondrial localization%) at different radial distances from zymosan. 
Data shown is 53 zymosan particles from 5 images. Data were analysed by a one-way 
ANOVA (p<0.0001) with a linear regression post-test shown. f) Box&whisker plots 
showing quantification of size for >800 mitochondrial units per group taken from 5 images 
 of Res in the presence or absence of zymosan-AlexaFluor488. g) Representative pictures 
(left) of microbial plates with Saccharomyces cerevisiae (S. cerevisiae) colonies. Data 
shown is from S.cerevisiae Đultuƌed ±Res ǁith atpeŶiŶ Aϱ ;ϭμMͿ oƌ ĐoŶtƌol foƌ ϰ½ houƌs. 
The graph on the right shows quantification of the average microbial killing. Data are from 
3 experiments (n=13 per group) and were analysed by two-way ANOVA (interaction + 
experimental repeat p=0.26, antimycin A p=0.10). h) Representative pictures (left) and 
ƋuaŶtifiĐatioŶ of data ;ƌightͿ as iŶ ;EͿ, ďut ǁith aŶtiŵǇĐiŶ A ;ϭμMͿ oƌ ĐoŶtƌol. Data is fƌoŵ 
4 experiments (n=18 per group) and were analysed by two-way ANOVA (interaction + 
experimental repeat p=0.10, antimycin A p<0.0001). Whiskers (e-h) show 10-90% of the 
range. White scale bars are 10?m.  
 Figure 10: Peritoneal tissue-resident macrophages are metabolically poised to engage 
microbes using tissue-niche fuels 
Model showing the proposed metabolic phenotypes of resting- and phagocytic- 
peritoneal tissue-resident macrophages and how this impacts function. NAA = N-acetyl 
aspartate, PKC = Protein kinase C, Shuttles = malate-aspartate or citrate-malate 










Proportional	 abundances	 of	 macrophage	 metabolites	 are	 distinct	 and	 reveal	 significant	
enrichment	of	peritoneal	tissue-resident	macrophage	TCA	cycle	metabolites	
a)	 Heat-map	 showing	 the	 log10	 difference	 from	 the	 average	metabolite	 peak	 areas	 from	Gas	
Chromatography-Mass	 Spectrometry	 of	 363	 metabolites	 between	 3	 independent	 peritoneal	
tissue-resident	macrophage	 (Resident)	and	6	 independent	bone	marrow-derived	macrophages	
(BMDM)	extracts.	b)	these	data	were	analysed	with	Ingenuity	pathway	analysis	(IPA)	for	a	non-
biased	 view	 of	 enriched	 metabolic	 pathways,	 data	 shown	 is	 the	 minus	 log2	 p-value.	 Tissue-
resident	 macrophages	 were	 enriched	 for	 the	 putrescine	 biosynthesis	 pathway	 and	 TCA	
metabolites,	 while	 BMDM	 contained	 relatively	 higher	 levels	 of	 amino	 acids,	 characterized	 by	
enrichments	of	numerous	pathways,	but	mainly	transfer-ribonucleic	acid	(tRNA)	charging	(which	








Heat-map	 showing	 the	 differentially	 enriched	 pathways	 and	 Z-activation	 scores	 of	 two	 bone	
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marrow-derived	 (BMDM)	and	 two	peritoneal	 tissue-resident	macrophages	 (Res)	RNA	samples.	
The	data	reveal	differential	expression	of	different	metabolic	isoforms	between	Res	and	BMDM,	




















































































































































Peritoneal	 tissue-resident	 macrophages	 have	 larger	 mitochondrial	 networks	 than	 bone	
marrow-derived	macrophages	
a)	Scatter	plot	showing	the	mean	mitochondrial	volume	of	peritoneal	tissue-resident	(Res)	and	





















































































































































Heat-map	 showing	 the	 log10	 difference	 from	 the	 average	 metabolite	 peak	 areas	 from	 Gas	
Chromatography-Mass	 Spectrometry	 of	 189	 named	 metabolites	 between	 5	 independent	







Additional	 biological	 ligands	 can	 induce	 PKC-dependent,	 glutamine-dependent	 oxygen	
consumption	in	peritoneal	tissue-resident	macrophages	
	a)	Plot	 of	oxygen	 consumption	 rate	 (OCR)	 vs	 time	 in	 peritoneal	 tissue-resident	macrophages	
(Res).	Ligands	were	added	after	the	first	reading:	Saccharomyces	cerevisiae	(S.cer,	50μg/ml,	heat-




oxygen	consumption	 in	 the	absence	of	glutamine	 (the	values	were	normalized	 to	100%	 in	 the	
presence	of	glutamine).	c)	Bar	chart	showing	the	percentage	of	total	oxygen	consumption	induced	
by	ligands.	The	values	show	the	maintenance	of	ligand-induced	oxygen	consumption	after	a	1h	
pre-treatment	 with	 the	 protein	 kinase	 C	 (PKC)	 inhibitor	 sotrastaurin	 (5µM)	 (the	 values	 were	
normalized	to	100%	with	vehicle	control).	Data	are	pooled	from	2-4	independent	experiments	(b:	
n=7-14	c:	n=13-20)	and	were	analysed	by	two-way	ANOVA	with	depicted	Sidak’s	post-tests;	(b):	
interaction	p=0.2883,	different	 stimuli	p=0.2527,	effect	of	glutamine	p<0.0001;	 (c):	 interaction	






a)	 Representative	 density	 plot	 showing	bone	marrow-derived	macrophage	 (BMDM)	uptake	of	
pHrodo	zymosan	particles	(50μg/ml)	after	1h.	Data	are	from	one	experiment	(n=3	separate	wells	












on	 the	 axis	 depicts	 typical	 production	 of	 bone	marrow-derived	macrophage	 nitrate	 24h	 after	






Peritoneal	 tissue-resident	 macrophages	 lacking	 TLR2	 localize	 their	 mitochondria	 to	 the	
phagolysosome	
Graphs	 showing	 quantification	 of	 the	 number	 of	 Mitotracker	 positive	 pixels	 expressed	 as	 a	






























































































































































































































































































































































































































Graph	 showing	 a	 dilution	 of	 trypan	 blue	 absorbance	 (590nm)	with	 phosphate	 buffered	 saline	
(mock	peritoneal	fluid	volume).	The	dotted	lines	represent	actual	peritoneal	lavages	with	trypan	
blue	(n=4),	which	record	a	peritoneal	volume	of	98.18±5.69	(mean±standard	error	of	the	mean)	
by	trypan	dilution.	The	data	represent	at	least	two	independent	experiments.	
	
